Clinical Trial

The Use of Shengmai San to Prevent Anthracycline Sequential Trastuzumab Therapy Related Cardiac Toxicity

Name: The Use of Shengmai San to Prevent Anthracycline Sequential Trastuzumab Therapy Related Cardiac Toxicity — clinical trial record (NCT06214195)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Study acronym: START

Recruiting Phase 3

View on ClinicalTrials.gov →

Summary

To evaluate the effectiveness and safety of Shengmai San in preventing anthracycline sequential trastuzumab therapy related cardiac toxicity through a prospective randomized controlled study.

Trial Details

NCT Number	NCT06214195
Lead Sponsor	Zhejiang Cancer Hospital
Conditions	Cardiotoxicity Induced by Drug Therapy for Breast Cancer
Enrollment	276 participants
Start Date	2024-01-20
Primary Completion	2026-12-01 (estimated)
Study Completion	2030-12-01 (estimated)
Updated on ClinicalTrials.gov	2024-01-19